Stoke Therapeutics $125 million stock and pre-funded warrants offering
The common stock is listed on the Nasdaq Global Select Market
Davis Polk advised the sole book-running manager and underwriter in connection with an upsized public offering by Stoke Therapeutics, Inc. of 5,555,557 shares of common stock at $13.5000 per share and pre-funded warrants to purchase 3,703,730 shares of common stock at $13.4999 per pre-funded warrant, for total gross proceeds of approximately $125 million. The common stock is listed on the Nasdaq Global Select Market under the symbol “STOK.”
Headquartered in Bedford, Massachusetts, Stoke Therapeutics is a clinical-stage company dedicated to addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels.
The Davis Polk capital markets team included partner Deanna L. Kirkpatrick, counsel Jeffrey S. Ramsay and associate Jenny Li. Partner David R. Bauer and associates Adrian Rabin and Lizzy Pott provided intellectual property advice. The tax team included partner Michael Mollerus and associate Michelle Zhao. All members of the Davis Polk team are based in the New York office.